0.00Open0.00Pre Close0 Volume0 Open Interest15.00Strike Price0.00Turnover232.75%IV-60.26%PremiumOct 18, 2024Expiry Date5.64Intrinsic Value100Multiplier20DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.7195Delta0.0660Gamma1.49Leverage Ratio-0.0413Theta-0.0059Rho-1.07Eff Leverage0.0074Vega
Foghorn Therapeutics Stock Discussion
loading...
NEWS
Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants
NEWS
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
Foghorn Therapeutics Inc. (Nasdaq: FHTX) announced plans to host a conference call and webcast on April 9th to review key pipeline programs, including FHD-286 for AML and new preclinical data for FHD-909 and selective CBP and EP300 degrader programs.
No comment yet